Table 2 This table shows additional outcomes for some studies

1. Benotmane et al. 2022 [38]

Only 3 of 416 patients had entered ICU

2. Kaminski et al. 2022 [45]

–

Within (333), (2) COVID-19-related hospitalization in the intensive care unit

Only 2 of 333 patients had entered the ICU in the intervention group; in the control group, six from 7 had entered the ICU

3. Nguyen et al. 2022 [27]

–

–

6 of 49 patients needed oxygen

4. Lafont et al. 2022 (for prophylaxis) [28]

–

1 of 15 had entered the intervention group, but two of 10 in the control group

2 of 15 patients needed oxygen in the intervention group. However, in the control group, three out of 10 needed oxygen

5. Lafont et al. 2022 (for treatment) [28]

Not reported

Within a total of l 42, (5) reported oxygen requirements, (12) hospitalization, (2) intensive care

Within a total of l 42, (2) reported asymptomatic, (26) fever, (28) cough, (15) dyspnea,

2 of 13 had entered the ICU in the intervention group, but two of 10 in the control group

2 of 13 patients needed oxygen in the intervention group, but in the control group, there were three from 10

6. Ordaya et al., 2022 [30]

Only two individuals had severe respiratory symptoms, while other patients showed mild respiratory symptoms with no mortality

Within eight patients: (2) showed bacterial complications, and (1) needed oxygen therapy

Ranging from asymptomatic to cough, dyspnea,

Only one patient out of 8 needed oxygen

7. Levin et al., 2022 (PROVENT) [11]

Total 3461 include (64) sever, (50) serious, and (93) particular interest adverse events, including (82) Injection-site reactions

–

9. Thomas L et al.,2022 [38]

ACTIV-3-(TICO) [37]

–

Of 710 patients, 17 sustained recovery in the intervention group, but 595 from 707 sustained recovery in the control

10. Karaba et al. 2022 [46]

Through 7 days of any T+C injection, no subjects stated any adverse cardiac events, hypersensitivity reactions, or acute organ rejection (reactions that were reported were mild to moderate)

11. Jondreville et al. 2022 [41]

Only one patient of, 161 had significant adverse events

12. Calabrese et al. 2022 [37]

Only one of 412 patients had significant adverse events

11 of 412 patients had mild symptoms

13. Goulenok et al. 2022 [49]

None from 10 patients had a severe illness in the intervention group, but in the control group, four of 7 patients had severe illness symptoms

14. Bertrand et al. 2022 [44]

Only 2 of 412 patients had severe illness symptoms in the intervention group. However, in the control group, 6 160 had severe illness symptoms

In the intervention group, 2 of 412 entered the ICU, but in the control group, entered the ICU